[{"orgOrder":0,"company":"Belharra Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Belharra Therapeutics","amount2":2.0800000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":2.0800000000000001,"dosageForm":"","sponsorNew":"Belharra Therapeutics \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Belharra Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Belharra Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Belharra Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Belharra Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Belharra Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Belharra Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Belharra Therapeutics","amount2":0.73999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.73999999999999999,"dosageForm":"","sponsorNew":"Belharra Therapeutics \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Belharra Therapeutics \/ Sanofi"}]

Find Clinical Drug Pipeline Developments & Deals by Belharra Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The collaboration will leverage Belharra’s proprietary, non-covalent chemoproteomics platform to identify and advance small molecules against Sanofi-designated immunology targets.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $40.0 million

                          June 18, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Discovery Platform

                          Sponsor : Sanofi

                          Deal Size : $740.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Belharra will be responsible for discovery and early preclinical development of small molecules against Genentech’s designated targets, while Genentech will be responsible for late preclinical, clinical, and regulatory development, and commercializatio...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $80.0 million

                          January 04, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Genentech

                          Deal Size : $2,080.0 million

                          Deal Type : Collaboration

                          blank

                          03

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Belharra’s integrated chemoproteomic-based drug discovery engine addresses the limitations of traditional screening approaches through a proprietary library of photoaffinity-based chemical probes that explore protein-ligand interactions in the native e...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 04, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Sponsor : Versant Ventures

                          Deal Size : $50.0 million

                          Deal Type : Series A Financing

                          blank